Early interneuron dysfunction in ALS: Insights from a mutant sod1 zebrafish model
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective: To determine, when, how, and which neurons initiate the onset of pathophysiology in amyotrophic lateral sclerosis (ALS) using a transgenic mutant sod1 zebrafish model and identify neuroprotective drugs. Methods: Proteinopathies such as ALS involve mutant proteins that misfold and activate the heat shock stress response (HSR). The HSR is indicative of neuronal stress, and we used a fluorescent hsp70‐DsRed reporter in our transgenic zebrafish to track neuronal stress and to measure functional changes in neurons and muscle over the course of the disease. Results: We show that mutant sod1 fish first exhibited the HSR in glycinergic interneurons at 24 hours postfertilization (hpf). By 96 hpf, we observed a significant reduction in spontaneous glycinergic currents induced in spinal motor neurons. The loss of inhibition was followed by increased stress in the motor neurons of symptomatic adults and concurrent morphological changes at the neuromuscular junction (NMJ) indicative of denervation. Riluzole, the only approved ALS drug and apomorphine, an NRF2 activator, reduced the observed early neuronal stress response. Interpretation: The earliest event in the pathophysiology of ALS in the mutant sod1 zebrafish model involves neuronal stress in inhibitory interneurons, resulting from mutant Sod1 expression. This is followed by a reduction in inhibitory input to motor neurons. The loss of inhibitory input may contribute to the later development of neuronal stress in motor neurons and concurrent inability to maintain the NMJ. Riluzole, the approved drug for use in ALS, modulates neuronal stress in interneurons, indicating a novel mechanism of riluzole action. ANN NEUROL 2013;73:246–258
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circuits controlling vertebrate locomotion: moving in a new direction
Goulding, M. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2608 · Cited by 777 · cited 2×
“Of these, the CoBL and CoSA interneurons are pax2 positive.(18,25,26) We therefore used anti-pax2 antibodies to label CoBL and CoSA interneurons.”
BackgroundMethodPathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders
Jucker, M., & Walker, L. C. (2011) · Annals of Neurology · doi:10.1002/ana.22615 · Cited by 622 · cited 1×
“Emerging data indicate that protein misfolding may be of mechanistic importance in these diseases.(1) Mutations in the ubiquitously expressed superoxide dismutase (SOD1) gene account for 20% of cases of the familial form of ALS.”
BackgroundMolecular pathways of motor neuron injury in amyotrophic lateral sclerosis
Ferraiuolo, L., Kirby, J., Grierson, A. J., Sendtner, M., & Shaw, P. J. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.152 · Cited by 615 · cited 10×
“The major impetus for developing the zebrafish ALS model is their suitability for high-throughput drug screening, thereby facilitating discovery of drugs that ameliorate ALS.”
BackgroundInfluentialSelf-citationA topographic map of recruitment in spinal cord
McLean, D. L., Fan, J., Higashijima, S.-I., Hale, M. E., & Fetcho, J. R. (2007) · Nature · doi:10.1038/nature05588 · Cited by 384
Cited by
Ciura, S., Lattante, S., Le Ber, I., Latouche, M., Tostivint, H., Brice, A., & Kabashi, E. (2013) · Annals of Neurology · doi:10.1002/ana.23946 · Cited by 333
“More recently, zebrafish models have been increasingly used for genetic and pharmacological screens to identify key modifiers of neurodegenerative processes(22,28,29) as well as to identify pathophysiological mechanisms involved in motor neuron diseases.(30,31) Here we describe a genetic model of C9orf72 loss of funct…”
BackgroundGoing the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases
Armada-Moreira, A., Gomes, J. I., Pina, C. C., Savchak, O. K., Gonçalves-Ribeiro, J., Rei, N., Pinto, S., Morais, T. P., Martins, R. S., Ribeiro, F. F., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00090 · Cited by 317
Zebrafish models in neuropsychopharmacology and CNS drug discovery
Khan, K. M., Collier, A. D., Meshalkina, D. A., Kysil, E. V., Khatsko, S. L., Kolesnikova, T., Morzherin, Y. Y., Warnick, J. E., Kalueff, A. V., & Echevarria, D. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13754 · Cited by 204
Modelling amyotrophic lateral sclerosis: progress and possibilities
Van Damme, P., Robberecht, W., & Van Den Bosch, L. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.029058 · Cited by 204
“In a compound screening, riluzole and apomorphine (an activator of the regulator of resistance to oxidative stress, nuclear factor erythroid 2-related factor 2 or NRF2) counteracted this interneuron dysfunction (McGown et al., 2013).”
Animal models of multiple sclerosis: From rodents to zebrafish
Burrows, D. J., McGown, A., Jain, S. A., De Felice, M., Ramesh, T. M., Sharrack, B., & Majid, A. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518805246 · Cited by 135
Self-citationLattante, S., de Calbiac, H., Le Ber, I., Brice, A., Ciura, S., & Kabashi, E. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu580 · Cited by 90
Metadata
- Authors
- McGown, A., McDearmid, J. R., Panagiotaki, N., Tong, H., Al Mashhadi, S., Redhead, N., Lyon, A. N., Beattie, C. E., Shaw, P. J., & Ramesh, T. M.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-12-31
- Volume
- 73
- Issue
- 2
- Pages
- 246-258
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1526054140
- Cited by
- 91
- References
- 4
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.